Krystal Biotech, Inc.
KRYS
NASDAQ·Healthcare·Biotechnology·Mkt cap $10.6B
$358.24
▼ -3.56%
P/E
44.12
Mkt Cap
$10.6B
52-Wk Range
$136.73–$382.54
52-Week Range
$136.73 - $382.54
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 146.7% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary redosable gene therapy platform enabling repeat dosing
- First-mover advantage in DEB gene therapy with Phase III clinical data
- Diversified pipeline addressing multiple rare disease indications
- Focused expertise in cutaneous and genetic disorder applications
Bear Case
2 risks
- Low volatility (beta 0.5).
- High premium - requires strong execution
Growth
Moderate growth ahead
Phase III clinical trial progression and potential FDA approval of B-VEC
Value
High premium - requires strong execution
Momentum
Strong
+18.7% over 3m
Quality
Excellent
Excellent business quality
Dividend
None
No dividend
Smart-money signal
Who's buying KRYS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 2, 2026
AUG 3, 2026
Reported EPS of $1.79 vs $1.70 consensus (+5.3% surprise). Revenue of $119.2M vs $120.9M expected (-1.4%).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+5.3%
Revenue trend · last 8Q
—
+116%
+95%
+37%
+17%
+18%
+32%
+24%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$83.8M
$91.1M
$88.2M
$96.0M
$97.8M
$107.1M
$116.4M
$119.2M
Margins · last 8Q
Gross
94.6%
Operating
49.0%
Profit
45.9%
Wall Street consensus
5 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: RBC Capital · Aug 14, 2026
vs Industry
How KRYS stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related